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Abstract
Background—Major organizations recommend cytology screening (Pap test) every 3 years for 
women aged 21–65; women aged 30 to 65 have the option of adding the HPV test (co-test) every 5 
years. We examined national percentages of cervical cancer screening, and we examined use of co-
testing as an option for screening.
Methods—We used 2015 U.S. National Health Interview Survey (NHIS) data to examine recent 
cervical cancer screening (Pap test within 3 years among women aged 21–65without a 
hysterectomy; N = 10,596) and co-testing (N = 9,125). We also conducted a multivariable analysis 
to determine odds of having had a Pap test or co-test by demographic variables. To evaluate 
changes in screening over time, we examined Pap testing during the years 2000, 2005, 2008, 2010, 
2013 and 2015. Analysis completed in Atlanta, GA during 2016.
Results—Overall, 81.1% of eligible women reported having a Pap test within 3 years; 
percentages declined over time among all age groups. An estimated 14 million women aged 21–65 
had not been screened within the past 3 years. Recent immigrants to the United States, women 
without insurance, and women without a usual source of healthcare had lower odds of being up to 
date with screening. About 1/3 of women up to date on Pap testing reported having a co-test with 
their most recent Pap test.
Conclusions—Declines in screening among women aged 21–65 are cause for concern. More 
research is needed on co-testing practices. Provider and patient education efforts may be needed to 
clarify recommended use of HPV tests.
Keywords
Pap test; HPV DNA test; Cervical cancer; Cancer screening; Cytology
*Corresponding author at: Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention, 
Centers for Disease Control and Prevention, 1600 Clifton Road, NE MS-E47, Atlanta GA 30333, United States. eze5@cdc.gov (M. 
Watson). 
Disclaimer
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention.




Prev Med. Author manuscript; available in PMC 2018 July 01.
Published in final edited form as:














In the United States, cervical cancer screening has proven to be extremely successful, 
resulting in declining incidence and mortality rates, although recent statistics suggest 
declines in mortality have stabilized (Ryerson et al., 2016; Saraiya et al., 2013; Benard et al., 
2014). In 2012, major organizations that issue guidelines on cervical cancer screening 
recommended cytology screening (Pap test) every 3 years for women aged 21–65;women 
aged 30 to 65 have the option of adding the HPV test (co-test) every 5 years (Centers for 
Disease Control and Prevention, 2013).
Healthy People provides national objectives for improving the health of all Americans. The 
Healthy People 2020 (HP2020) cervical cancer objective is to increase the proportion of 
women aged 21–65 who receive a screening based on the most recent guidelines to 93% 
(Healthy People 2020, 2016). Analyses of national data from 2013 showed that the 
percentage of recommended screening (every 3 years among women aged 21–65) had not 
yet attained this objective, and in fact were declining (Sabatino et al., 2015).
The purpose of this study was to examine the most recent national survey data (2015) on 
cervical cancer screening in accordance with current recommendations to assess progress 
toward HP2020 objectives, and to examine national data on the use of co-testing as an option 
for screening.
2. Methods
We used data from the 2015 U.S. National Health Interview Survey (NHIS) to examine 
recent cervical cancer screening. NHIS is a cross-sectional household survey conducted in 
person in English or Spanish and representative of the civilian, noninstitutionalized US 
population (National Center for Health Statistics, Centers for Disease Control and 
Prevention, 2016a). One sample adult aged ≥18 years and sample child (if present) in each 
family are randomly selected for additional detailed questions. We used the Sample Adult 
file, which had a response rate of 55.2% for 2015 (National Center for Health Statistics, 
Centers for Disease Control and Prevention, 2016b). We also used the Person and Imputed 
Income files for additional information. The overall proportions of persons screened were 
presented as crude percentages and age standardized to the 2000 U.S. standard population.
We considered having had a Papanicolaou (Pap) test within 3 years as being up to date with 
screening. Women age 18+ who reported ever having had a Pap test were asked the NHIS 
question: When did you have your MOST RECENT Pap test? In order to assess information 
on co-testing, these women were also asked: An HPV test is sometimes given with the Pap 
test for cervical cancer screening. Did you have an HPV test with your most recent Pap test? 
We limited our analysis to women recommended for screening: age 21–65 years, not having 
had a hysterectomy.
We examined screening by race/ethnicity (white, black, and Asian [all non-Hispanic], and 
Hispanic [regardless of race]), age group, U.S. residence, education level, family income (% 
of federal poverty threshold), usual source of health care, and health care insurance 
coverage. Insurance includes public or private health care coverage, but excludes Indian 
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Health Service coverage or single service plans (i.e., that pay for only one type of service). 
We also examined the odds ratios of these variables in a multivariate analysis, to determine 
which of these factors may be most strongly associated with cervical cancer screening. 
NHIS data from2000, 2005, 2008, 2010, 2013, and 2015 were used to evaluate changes in 
cervical cancer screening percentages over time. We used two test timing recodes for NHIS 
data, depending on the year or years analyzed. Timing recode “A” was used for 2015 data 
(NHIS variable RPAP3A1) (National Center for Health Statistics, Centers for Disease 
Control and Prevention, 2016a). This recode is available for 2005 and forward data, and 
provides the most accurate estimates. The timing recode “B”, used for 2000–2015 trends, 
uses the year 2000 estimation method and assumptions for missing data (NHIS variable 
RPAP3B1). The “B” version results in slightly biased screening estimates, but allows for 
unbiased comparisons with the 2000 and 2003 data.
We used SAS-callable SUDAAN Version 9.3 for statistical analysis. Differences in 
demographic variables were considered statistically significant if 95% confidence intervals 
did not overlap. Percent change was calculated as the percentage receiving screening in 2015 
subtracted from the percentage screened in 2000, divided by the percentage screened in 
2000. Pearson Wald F tests were used to test for differences in rates across years. All 
statistics were weighted to account for unequal probability of selection and nonresponse.
3. Results
Overall, 81.1% of women aged 21–65 reported having a Pap test within 3 years, in 
accordance with recommendations (Table 1). Non-Hispanic Asian and Hispanic women had 
lower percentages of Pap test within 3 years (73.5% and 76.9, respectively) than non-
Hispanic white and non-Hispanic black women (82.6% and 84.5%, respectively). Only 
66.8% of women in the United States < 10 years reported a recent screening, compared to 
77.0% of those in the united States > 10 years and 82.8% of US = born women. About 1/3 of 
women up to date on Pap testing reported having a co-test at their most recent screening. Co-
testing percentages were highest among non-Hispanic black women and lowest among non-
Hispanic Asian women (35.2% and 21.4%, respectively). Co-testing varied by age. Among 
women up to date with Pap testing, 30–39 year olds most commonly reported a co-test 
(41.0%), followed by 21–29 (38.2%) year olds.
We conducted a multivariable analysis to calculate odds ratios of receipt of cervical cancer 
screening, adjusting for other variables (Table 2). Compared with non-Hispanic white 
women, non-Hispanic black women had higher odds of reporting up to date Pap tests 
(adjusted OR 1.44; 95% CI 1.15–1.81), while non-Hispanic Asian women had lower odds 
(OR 0.53, 95% CI 0.39–0.73). Women age 30–39 years had higher odds than women of 
other ages of being up to date with cervical cancer screening. Lower odds of reporting a Pap 
test was associated with being in the United States < 10 years, no health coverage, and no 
usual source of health care. Higher odds of reporting a Pap test were associated with having 
higher income and a college degree.
Results for the multivariate analysis to determine odds of having had a co-test at the most 
recent screening were similar to those for being up to date with Pap test screening, with a 
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few exceptions. Hispanic women, in addition to non-Hispanic black women, had higher odds 
of reporting a co-test than white women. Differences in co-testing among women aged 21–
29 and women aged 30–39 were not statistically significant (OR 0.89; 95% CI 0.73, 1.08 
compared to referent group). US-born women had higher odds of reporting co-testing than 
foreign-born women. As with recent Pap testing, co-testing generally appeared to increase 
with educational attainment in the adjusted analysis, and uninsured women had lower odds 
of co-testing than women with some type of insurance.
We observed small, though statistically significant, declines in Pap testing among women 
aged 21–65 from 2000 to 2015 (−5.8%, Pearson Wald F test for trend p < 0.001; Fig. 1). 
Screening percentages were lowest and declined the most (10.6%) among women aged 21–
29, from 86.8% in 2000 to 77.6% in 2015 (test for trend p < 0.001). Women aged 30–39 had 
the highest screening percentages and the smallest declines over time.
4. Discussion
Over 80% of women reported being screened with a Pap test in accordance with 
recommendations; however, declines are cause for concern, and trends are not approaching 
the HP2020 objective (93% of eligible women screened). However, the nearly 20% of 
women were not screened within the past 3 years translates to > 14 million women aged 21–
65. No demographic group of women examined obtained the national objective, and 
consistent with previous research, some groups had markedly lower screening prevalence 
(Tsui et al., 2007). For example, non-Hispanic Asian women had lower screening 
percentages compared to non-Hispanic white and non-Hispanic black women, and this 
difference was statistically significant in the adjusted analysis. Also, only 66.8% of foreign-
born women living in the United States for < 10 years were recently screened in accordance 
with recommendations. Previous studies have documented that foreign-born women are less 
likely to be screened, especially recent immigrants (Tsui et al., 2007; Tangka et al., 2015). 
Uninsured women were also less likely to be screened (61.2%), despite federal programs to 
provide screening services to these women (Tangka et al., 2015).
Nearly one-third of women who were up to date with Pap testing reported having had a co-
test at their most recent screening. Overall patterns of co-testing mirrored those for Pap 
testing, with a few exceptions. Co-testing varied by age, with the highest percentages among 
those younger than age 40.
Among women aged 21–29 who were up to date with screening guidelines, 38% reported 
having had a co-test at their most recent screening. Co-testing is not recommended as part of 
screening for women younger than age 30. A small proportion of HPV tests among women 
aged 21–29 may have been conducted according to guidelines, because women of any age 
diagnosed with atypical squamous cells of undetermined significance (ASC-US) can be 
tested for HPV to determine next steps. Some prior recommendations recommended “reflex 
testing” of abnormal Pap test results to determine whether abnormal results were HPV-
positive or not (Saraiya et al., 2013). Inaccurate self-report may also contribute to findings. 
Nearly 1 in 5 women overall (17%) reported not knowing whether or not they had had an 
HPV test at their most recent screening (data not shown). This percentage varied by age, 
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with only 13% of women aged 20–29 reporting being unsure of whether they had been 
tested for HPV during their most recent screening, and higher proportions among women 
over age 40 (19%). Liquid-based Pap tests allow for the use of HPV tests without taking an 
additional sample (Committee on Practice Bulletins–Gynecology, 2016), and women may 
not be informed of co-test use except in the case of positive results. Potential overuse of 
HPV tests among women aged 21–29 and lack of information about whether HPV tests were 
used in screening highlight the need for increased provider and patient education regarding 
use of co-tests.
In 2014, the FDA approved use of one HPV test as primary screening for women aged 25 
and older (U.S. Food and Drug Administration, 2014). Although current screening 
guidelines do not recommend primary screening via HPV test, representatives from several 
organizations including the American Cancer Society, the American Society for Colposcopy 
and Cervical Pathology, and the American Society for Clinical Pathology have issued 
interim guidance for clinicians wishing to use the HPV test as primary screening (Centers 
for Disease Control and Prevention, 2013; Huh et al., 2015). We were not able to identify 
women using the HPV test as primary screening, because this modality was not in use at the 
time of development of the NHIS questions.
In 2006, the first vaccine protecting against HPV infection was approved for use in the 
United States (Centers for Disease Control and Prevention, 2007). Soon after the vaccine 
approval, there was concern that women who had been vaccinated against HPV might be 
less likely to participate in cervical cancer screening (Kulasingam et al., 2007). Our 
preliminary analysis showed that on the contrary, vaccinated women of all ages, as well as 
those aged 21–29, were more likely to be screened than unvaccinated women. These 
findings are consistent with previous research (Chao et al., 2017). Associations between 
vaccine receipt and cervical cancer screening were not significant in the multivariate 
adjusted analysis. Socioeconomic factors such as education, income, and health insurance 
were important variables in our model, and are likely to be positively associated with both 
HPV vaccination and cervical screening. One modeling study suggests that HPV vaccination 
will reduce overall screening rates, but that current inequities will persist as long as some 
populations have low rates of vaccination and screening (Malagon et al., 2015). Future 
studies to determine factors in screening by HPV vaccination status may elucidate additional 
important findings.
While current screening guidelines remain consistent for vaccinated and unvaccinated 
women, recommendations for screening might differ by HPV vaccination status in the 
future, or screening intervals may lengthen for all women if the prevalence of high-risk HPV 
reaches low enough levels in the population. As vaccine rates increase the prevalence of 
abnormal lesions, especially high-grade, is expected to decrease, reducing the specificity of 
cytology (Rodriguez et al., 2013). Primary HPV testing with cytology used as a follow-up 
may be a more effective way to screen vaccinated women (El-Zein et al., 2016).
Watson et al. Page 5














To our knowledge, this is the first examination of nationally representative data examining 
HPV test use in cervical cancer screening. Our paper also provides updated information on 
cervical cancer screening, providing information with which to monitor success toward 
HP2020 objectives. Despite these strengths, we did identify some limitations. First, the 
NHIS question currently asks women if they were screened for HPV “with your most recent 
Pap test”. This wording does not allow for women to report whether they have had the HPV 
test as a primary test (separate from Pap test), or whether they have had an HPV test at 
another time other than at the last Pap test. Also, because this is the first use of HPV test 
questions, future versions of the survey may identify improvements on the question. Many 
women (17%) reported not knowing whether they had a HPV test or not. Because the NHIS 
uses self-report data, these data may be less accurate than medical records.
While many cancer screening questions have high validation scores when compared with 
medical data, cervical cancer screening is frequently over reported, and women frequently 
confuse Pap testing with pelvic exams for other reasons (Rauscher et al., 2008). Questions 
on HPV testing may be subject to similar concerns, especially since women aged 21–30 
were most likely to report having had an HPV test despite the fact that HPV testing is not 
recommended for women younger than age 30. Studies using medical records to validate 
self-report of co-tests are needed to determine the accuracy of co-test data. Also, given 
variability of screening intervals as well as multiple options for test types, new methods may 
be needed to accurately assess cervical cancer screening. One method has been proposed to 
ask women first if they have ever been screened, the timing of the most recent test, and then 
the type of test used (Lowe et al., 2015).
We do not have longitudinal data over time from the same women enabling us to look at the 
frequency of screening. As guidelines have changed from one-year screening intervals to 
three- or five-year intervals, it would be helpful to better understand patterns of screening 
intervals. Also, we defined being up to date on screening as having had a Pap test within 3 
years; it is possible that some women had co-tests and are extending intervals to 5 years. A 
related analysis found that including these women increased the age-adjusted percentage of 
women screened according to guidelines to 83.0% (compared to 81.4% in our analysis) 
(White et al., 2017). Finally, while this is a large and robust national survey, there is always 
the possibility of nonrandom survey sampling errors with survey data.
6. Conclusions
This study provides important new information on the use of HPV tests in screening. 
Provider and patient education may be needed to clarify when HPV tests are being 
administered, what they are for, and for which populations (women age 30 to 65). Declines 
in screening among women aged 21–65 are cause for concern. Certain populations, such as 
recent immigrants and uninsured women, have very low percentages of screening that need 
to be addressed. If declines in cervical cancer are to be continued, more efforts may be 
needed to reach rarely-or never-screened women.
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Trends in cervical cancer screening (Pap test) within 3 years, United States, 2000–2015. All 
trends 2000–2015 statistically significant (p < 0.01). NHIS question for Pap test: When did 
you have your MOST RECENT Pap test? NHIS question for co-test: An HPV test is 
sometimes given with the Pap test for cervical cancer screening. Did you have an HPV test 
with your most recent Pap test? Data analysis completed in Atlanta, GA during 2016.
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Table 2
Adjusted odds ratios of Pap testing and co-testing within 3 years by demographic variables, United States, 
2015.





OR 95% CI OR 95% CI
Race/ethnicity
  Hispanic 1.19 (0.89, 1.60) 1.31 (1.03, 1.66)
  Non-Hispanic White 1.00 (1.00, 1.00) 1.00 (1.00, 1.00)
  Non-Hispanic Black 1.44 (1.15, 1.81) 1.30 (1.08, 1.56)
  Non-Hispanic Asian 0.53 (0.39, 0.73) 0.68 (0.50, 0.94)
  Non-Hispanic other 0.68 (0.34, 1.35) 0.90 (0.53, 1.53)
Age in years
  21–29 0.55 (0.43, 0.71) 0.89 (0.73, 1.08)
  30–39 1.00 (1.00, 1.00) 1.00 (1.00, 1.00)
  40–49 0.69 (0.54, 0.88) 0.57 (0.48, 0.69)
  50–65 0.57 (0.45, 0.72) 0.34 (0.28, 0.41)
Period of U.S. residence
  US-born 1.00 (1.00, 1.00) 1.00 (1.00, 1.00)
  In United States <10 years 0.56 (0.39, 0.80) 0.48 (0.32, 0.71)
  In United States ≥10 years 0.87 (0.67, 1.13) 0.73 (0.56, 0.95)
Education
  Less than high school 0.48 (0.35, 0.67) 0.67 (0.50, 0.90)
  High school graduate 0.52 (0.41, 0.65) 0.77 (0.62, 0.95)
  Some college/associate degree 0.65 (0.53, 0.80) 0.92 (0.78, 1.09)
  College graduate 1.00 (1.00, 1.00) 1.00 (1.00, 1.00)
% of federal poverty threshold
  <139% 0.63 (0.46, 0.85) 0.66 (0.52, 0.85)
  139%–250% 0.64 (0.49, 0.84) 0.72 (0.59, 0.88)
  251%–400% 0.80 (0.62, 1.03) 0.79 (0.64, 0.96)
  >400% 1.00 (1.00, 1.00) 1.00 (1.00, 1.00)
Usual source of care
  None or hospital emergency department 0.59 (0.45, 0.77) 0.99 (0.76, 1.29)
  Has usual source 1.00 (1.00, 1.00) 1.00 (1.00, 1.00)
Health care coverage
  Private 1.00 (1.00, 1.00) 1.00 (1.00, 1.00)
  Medicaid and other public 0.93 (0.74, 1.17) 0.95 (0.76, 1.18)
  Other coverage 1.15 (0.78, 1.70) 1.26 (0.94, 1.70)
  Uninsured 0.57 (0.43, 0.76) 0.72 (0.54, 0.97)
Abbreviations: CI = confidence interval; HPV = Human Papillomavirus; OR = odds ratio; Pap = Papanicolaou.
NHIS question for Pap test: When did you have your MOST RECENT Pap test?
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NHIS question for HPV test: An HPV test is sometimes given with the Pap test for cervical cancer screening. Did you have an HPV test with your 
most recent Pap test?
Data analysis completed in Atlanta, GA during 2016.
Prev Med. Author manuscript; available in PMC 2018 July 01.
